Jauhari Shekeab, Nasta Sunita D
Division of Hematology/Oncology, Duke University Medical Center, Durham, NC.
Division of Hematology/Oncology, Hospital of the University of Pennsylvania, Philadelphia.
Am J Hematol Oncol. 2016 Sep;12(9):8-13.
18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) has been the most important advance in the assessment of Hodgkin lymphoma (HL) since the introduction of computed tomography (CT). In the frontline management of HL, FDG-PET combined with low-dose CT has emerged as the modality of choice for staging and treatment response assessment. Substantial data have accumulated over the past several years supporting the use of PET/CT in the evaluation and management of relapsed or refractory HL, as well. In this article, we review the role of PET/CT after the frontline treatment of HL, as well as the prognostic utility of PET/CT before autologous and allogeneic stem cell transplantation. We also review the use of PET/CT as a part of response-adapted treatment strategies in relapsed or refractory HL and implications for current and future clinical practice.
自计算机断层扫描（CT）问世以来，18F-氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）一直是霍奇金淋巴瘤（HL）评估中最重要的进展。在HL的一线管理中，FDG-PET联合低剂量CT已成为分期和治疗反应评估的首选方式。在过去几年中积累了大量数据，支持将PET/CT用于复发或难治性HL的评估和管理。在本文中，我们回顾了PET/CT在HL一线治疗后的作用，以及PET/CT在自体和异基因干细胞移植前的预后效用。我们还回顾了PET/CT作为复发或难治性HL中适应性治疗策略一部分的应用及其对当前和未来临床实践的影响。
